The Science Behind Oral GLP

Oral GLP-1 receptor agonists (like semaglutide tablets) work in the same way as injectable GLP-1 drugs, but with some differences in absorption and delivery.

In the early 2000s, we started our work on oral delivery of biologic medicines. We began exploring different routes of administration, initially focused on insulin and GLP-1 . Through dedicated protein and peptide engineering efforts, we managed to create the first ever oral biologic of its kind - oral semaglutide for type 2 diabetes launched in ...
From needles to pills

Oral GLP-1 therapies represent a transformative step in obesity management, offering a convenient alternative that may broaden access and optimize individualized care. Keywords: Obesity, Oral GLP-1 , Orforglipron, Semaglutide, Weight loss For decades, the promise of a pill to treat obesity has hovered at the edges of imagination.
Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight. At the American Diabetes Association's Scientific Session, Mass ...

Oral GLP
To date, semaglutide is the only GLP-1 agent with an approved oral formulation. Given that use of oral semaglutide will inevitably increase, particularly with recent FDA approval for weight management on January 5, 2026, 2 there is a growing need to understand the impact of oral semaglutide on cardiovascular risk factors.
Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have evolved from glucose-lowering agents to transformative therapies across multiple organ systems. This comprehensive review synthesizes current evidence on the mechanisms, established ...

Overview of The Science Behind Oral Glp 1 Therapies
The future of GLP -1RA therapy is promising. Researchers are developing more efficient formulations, such as long-acting and oral versions, to improve patient compliance and outcomes. With ...
Wednesday, May 6, 2026 Oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings NIH-funded research identifies new mechanism of action for next-generation weight-loss drugs. A National Institutes of Health (NIH)-funded study has found that an emerging class of GLP-1 weight-loss drugs suppress eating for pleasure, or hedonic feeding, in mice by modulating a reward ...

Oral GLP
Therapy for type 2 diabetes with GLP-1 receptor agonists initially necessitated subcutaneous injection of a peptide analogue of the incretin hormone GLP-1.1 Oral administration of a GLP-1 receptor agonist was first achieved when the peptide semaglutide was co-administered with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl]amino) caprylate.2 With some inconvenience ( oral administration ...









A new experimental GLP-1 pill could make it easier for people with type 2 diabetes to access treatments that help control blood sugar and support weight loss.